Tag Archive for: Roche

T-Cell-Dendritic-Cell interaction. © Hookipa
partnership

HOOKIPA bags US$10m cancer milestone

HOOKIPA has received a US$10m milestone under its 2022 agreement with Roche to develop an arenaviral immunotherapy for KRAS-mutated cancers.

Read more
PD-L1 blocks PD-L1 and B7.1 receptors on T cells thus triggering inactivation of cytotoxic T cells. © Genbentech Inc
Approval

Roche withdraws checkpoint blocker from the market

Roche AG’s US subsidiary Genentech Inc has withdrawn its checkpoint inhibitor atezolizumab from the market after disappointing results in bladder cancer.

Read more
©Roche
Roche

Ring exchange at Roche’s top executive level

Schwan follows Franz, Schinecker follows Schwan.

Read more